Proposition 3 definition

Proposition 3. In the bargaining equilibrium, for any given k N , c N is decreasing in k S .
Proposition 3. With banks’ effort, when μe2 , Δ ( ) > ,that is, banks’ profits increase, where, (κ +θ )4 φ > κ 4 . E Rb 0 φ = − > 0 ⎣ ⎦ 2λ ⎡(κ +θ )2 + λρσ 2 ⎤ 2λ ⎡⎣κ 2 + λρσ 2 ⎤⎦ The difference of the incentive coefficients in two cases is as follows: ⎡ ΔE (R ) = E* (R ) − E* (R ) = ⎢ (κ + θ )4 − κ 4 ⎤ μe2 ⎥ −
Proposition 3. With quantity competition and uncertain cost or demand specific intercept, welfare is greater when both firms share if and only if B < δ2(20 − 3δ2)/(20 + δ2). Inspection of proposition 3 shows that there does not exist δ such that when the union has all of the pricing power (B=1), welfare increases with information sharing: for δ∈(-1,1), δ2(20 − 3δ2)/(20 + δ2) is increasing in δ, and at δ=1, δ2(20 − 3δ2)/(20 + δ2) = 17/21. The intuition is that the information leads the union to induce output changes that are in the opposite direction of what would increase welfare. A lower cost firm receives a higher wage and so produces less, while a higher cost firm receives a lower wage inducing it to produce more. On the other hand, when the union has relatively little pricing power, welfare increases from information sharing because of the interaction between the firms. Thus, as δ decreases (so that the interaction between the firms decreases) information sharing is less likely to raise welfare. That welfare decreases with information sharing when the union has the pricing power is the opposite of what is found in Li (2002), pointing to the effect of differential wages. Worse, comparing proposition 2 and 3 shows that the critical threshold in pricing power for producer surplus to increase is always greater than that for welfare. Thus, Corollary: With quantity competition and uncertain cost or demand specific intercept, for all δ∈(0,1), there exists a pricing power B such that the union can profitably induce the firms to share, but welfare decreases.

Examples of Proposition 3 in a sentence

  • Since the strategy profile is subgame-perfect, it follows from Proposition 3 that s > p, implying that αs > πs.

  • Note that every member can compute the group key (see Proposition 3) since: – All existing members only need the new member’s blinded session random.

  • While showing this we also obtained interesting side results, such as Proposition 3, which provides a novel characterization of weak pullback preservation.

  • Whether the agents only determine the most specific diagnoses depends on the type of diagnosis they use; i.e. consistency based or abductive based: Proposition 3 Pure abductive diagnosis may not produces less specific diagnoses.

  • Proposition 3 shows how wSNI bridges the gap between vanilla and general sandboxing.

  • For the second part of Proposition 3, first remark that, since b1(e1)−b1(e1−w1∗) is decreasing with e1 ∈ [e1, e¯1] for every w1∗ ∈ (0, ei), b1(e1) − b1(e1 − w1∗) ≥ b1(e1) − b1(e1 − w1∗) for every e1 ∈ [e1, e¯1] with a strict inequality for e1 > e1.

  • C Proof of Proposition 3 The proof of the first part of Proposition 3 is similar than the proof of Proposition 2.

  • Our initial scope of services included bidding and construction of one single project for Proposition 4 and one project for Proposition 3.

  • By Proposition 3, we have that NC1 (uπ(|U|)) = NG(uπ(|U|)) = NC2 (uπ(|U|)).

  • S succeeds with probability ((n − n1)2m)−1 Pr(E.2.1.1), and contradicts Proposition 3, unless Pr(E.2.1.1) is negligible.


More Definitions of Proposition 3

Proposition 3. An increase in the size of the northern region reduces the stability of the market sharing agreement.
Proposition 3. Shall Section 2 of Article II of the Charter be amended to clarify that the City’s authority to protect the health, safety, and welfare of the public shall be consistent with the laws and constitution of the United States as well as the State of Texas? □ For □ Against In the event that Proposition 3 is approved by the voters on November 4, 2014, Section 2 of Article II of the Pampa Charter shall thereafter read as follows:
Proposition 3. For any given k N , the smaller kS the higher c N . Proof: See Appendix CIn summary, this section shows that North gains more from aid tied to trade, than from free trade, and that North's share of the surplus created by cooperative solution is higher the poorer is the other country.
Proposition 3. If the sentence is harsh (l > t), then ∂p(l, t) > 0. If the sentence is ∂l S lenient (l > t), then ∂p(l, t) 0. ∂l In both Claim 1 and Proposition 3, either the actual or the target sentence is held constant. However, the general version of the conviction paradox would allow for both the actual sentence and the burden of proof to vary simultaneously.

Related to Proposition 3

  • Ballot proposition means a question, issue, or proposal that is submitted to voters

  • conformity assessment means the process demonstrating whether the requirements of this Regulation relating to a device have been fulfilled;

  • Proposal means the Technical Proposal and the Financial Proposal.

  • Phase 1 means the first implementation phase of this section, beginning June 1, 2018 and ending May 31, 2022.

  • Phase I means the first part of the tuition incentive assistance program defined as the academic period of 80 semester or 120 term credits, or less, leading to an associate degree or certificate.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase III means Phase I (or Phase I/II), Phase II (or Phase II/III) and Phase III clinical trials, respectively, in each case as prescribed by applicable FDA IND Regulations, or any corresponding foreign statutes, rules or regulations.

  • Study Completion means the database for the Study has been locked and all Essential Documents have been provided to the Sponsor, including a copy of the letter from the Reviewing HREC acknowledging receipt of the final report and/or closure letter from the Principal Investigator.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • ESA means the Federal Endangered Species Act of 1973, as amended (16 U.S.C. §§ 1531-1544) and all rules, regulations, and guidelines promulgated pursuant to that Act.

  • Phase 2 means the second implementation phase of this section, beginning June 1, 2022 and continuing thereafter.

  • Studies means activities needed to prepare project implementation, such as preparatory, mapping, feasibility, evaluation, testing and validation studies, including in the form of software, and any other technical support measure, including prior action to define and develop a project and decide on its financing, such as reconnaissance of the sites concerned and preparation of the financial package;

  • Treatability study means a study in which a hazardous waste is subjected to a treatment process to determine: (1) Whether the waste is amenable to the treatment process, (2) what pretreatment (if any) is required, (3) the optimal process conditions needed to achieve the desired treatment, (4) the efficiency of a treatment process for a specific waste or wastes, or (5) the characteristics and volumes of residuals from a particular treatment process. Also included in this definition for the purpose of the § 261.4 (e) and (f) exemptions are liner compatibility, corrosion, and other material compatibility studies and toxicological and health effects studies. A “treatability study” is not a means to commercially treat or dispose of hazardous waste.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Project Proponent means the individual or organization that has overall control and responsibility for the Project, or an individual or organization that together with others, each of which is also a Project Proponent, has overall control or responsibility for the Project. The entity(s) that can demonstrate Project Ownership in respect of the Project. For the avoidance of doubt where an individual executes this Representation in their capacity as an authorized office holder of the company who is the Project Proponent, this Representation is made by the company, not the authorized office holder;

  • Completion Deadline means the date by which the Arrangement is to be completed, which date shall be April 30, 2014 or such later date as may be agreed to in writing by the Parties;

  • Corrective Measure The contractor shall repair any deficiencies to meet the performance guideline within warranty period.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Project Proposal is the final and written description of the Project as described in Exhibit A, to be undertaken by Sub-recipient for which the Project Funds is granted and performance is required and monitored pursuant to this PFA.

  • Phase II means the second part of the tuition incentive assistance program which provides assistance in the third and fourth year of 4-year degree programs.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.